Hidroclorotiazida Bluefish (Hydrochlorothiazide)

Hidroclorotiazida Bluefish is indicated for several cardiovascular and renal conditions where reduction of excess fluid and blood pressure control are needed.

• Treatment of hypertension (high blood pressure).
• Management of edema associated with congestive heart failure.
• Reduction of fluid accumulation due to renal disease.
• Control of ascites and peripheral edema in liver cirrhosis.
• Adjunct therapy for other diuretics when additional fluid removal is required.

• Hydrochlorothiazide, the active component of Hidroclorotiazida Bluefish, inhibits the sodium‑chloride symporter located in the distal convoluted tubule of the nephron. By blocking this transporter, the drug reduces reabsorption of sodium and chloride, leading to increased excretion of sodium, chloride, and water in the urine. The resulting decrease in extracellular fluid volume contributes to lower blood pressure and alleviation of edema.

Adverse reactions to Hidroclorotiazida Bluefish can vary in frequency and severity.

Common

• Increased urination (polyuria).
• Low blood potassium levels (hypokalemia).
• Elevated blood sugar (hyperglycemia).
• Dizziness or light‑headedness, especially when standing.

Serious

• Severe electrolyte disturbances (e.g., hyponatremia, hypokalemia).
• Acute kidney injury.
• Allergic reactions such as rash, itching, or angioedema.
• Severe dehydration or hypotension.

Before starting Hidroclorotiazida Bluefish, certain health considerations should be reviewed.

• Assess kidney function and electrolyte status, especially potassium and sodium levels.
• Monitor blood pressure regularly to avoid excessive hypotension.
• Use caution in patients with diabetes, as the drug may affect blood glucose control.
• Evaluate for gout, as thiazides can increase serum uric acid.
• Discuss any history of liver disease or severe heart failure with a healthcare provider.
• Inform the prescriber of any concurrent use of other diuretics or antihypertensive agents.

Hidroclorotiazida Bluefish may interact with several medications, altering its efficacy or safety profile.

Avoid

• Lithium, due to increased risk of lithium toxicity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which can reduce diuretic effectiveness and impair kidney function.
• Digoxin, as electrolyte shifts may increase the risk of digoxin toxicity.

Use with caution

• ACE inhibitors or ARBs, which may enhance potassium loss.
• Antidiabetic agents, because blood glucose may rise.
• Corticosteroids, which can potentiate fluid and electrolyte disturbances.
• Anticoagulants, as volume changes may affect drug levels.